223786-50-3

Basic information

• Product Name: 1-(4-aminophenyl)piperidine-4-carboxamide
• Synonyms: 1-(4-aminophenyl)piperidine-4-carboxamide;1-(4-AMINOPHENYL)-4-PIPERIDINECARBOXAMIDE
• CAS NO: 223786-50-3
• Molecular Formula: C₁₂H₁₇N₃O
• Molecular Weight: 219.286
• Mol File: 223786-50-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 505.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.202±0.06 g/cm3(Predicted)
• PKA: 16.45±0.20(Predicted)
• CAS DataBase Reference: 1-(4-aminophenyl)piperidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-aminophenyl)piperidine-4-carboxamide(223786-50-3)
• EPA Substance Registry System: 1-(4-aminophenyl)piperidine-4-carboxamide(223786-50-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 223786-50-3(Hazardous Substances Data)

Usage

Chemical class

Carboxamides

Structure

Contains a piperidine ring and an aminophenyl moiety

Potential pharmaceutical applications

Therapeutic effects on the central nervous system

Interactions

With various neurotransmitter systems, including dopamine and serotonin

Possible uses

As an analgesic and antipsychotic agent

Significance

Compelling candidate for further research and development in medicinal chemistry

Upstream product

• 498-94-2 isonipecotic acid 
• 223786-53-6 1-(4-nitrophenyl)piperidine-4-carboxylic acid 
• 350-46-9 4-Fluoronitrobenzene 
• 39546-32-2 4-carboxamidopiperidine 
• 223786-49-0 1-(4-nitrophenyl)piperidine-4-carboxamide 

Downstream Products

• 223786-52-5 4-carboxamido-1-(4-isothiocyanato-phenyl)-piperidine 
• 714249-03-3 N-[(7-cyano-2-napthyl)methyl]-N-[4-(4-cyanopiperidin-1-yl)phenyl]methanesulfonamide 
• 714248-92-7 1-(4-{[(7-cyano-2-naphthyl)methyl]amino}phenyl)piperidine-4-carboxamide 

Relevant articles and documents

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.